WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 27-May-2016 (Data received as of 20-May-2016)
Next overall update Fall 2016
2015 data are provisionary
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 30'4451 Child (under 5 years) mortality rate: 32

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 10'543  10'543  10'545  10'545  10'534  10'263  10'324  10'338 
Births 107  108  108  110  111  88  127  163 
Surviving infants 107  107  108  109  110  88  125  160 
Pop. less than 5 years 538  547  560  573  577  447  647  893 
Pop. less than 15 years 1'586  1'565  1'547  1'531  1'515  1'687  2'225  2'418 
Female 15-49 years 2'427  2'451  2'476  2'500  2'521  2'605  2'579  2'439 

Number of reported cases

(Click for retrospective incidence data for Czech Republic (the))
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart
  222  15  22  17  2'420 
Mumps
ChartChart
  1'616  677  1'553  3'902  2'885  120 
Pertussis
ChartChart
  585  2'521  1'233  738  324  187  48 
Polio*
ChartChart
 
Rubella
ChartChart
  27  743 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Czech Republic (the))
Vaccine year result method % card seen                                                
BCG          99 
DTP1         
DTP3          99  98 
DTP4          97  99 
IPV1         
HepB_BD         
HepB3          97  99  99  99  99 
Hib3          97  99  99  99  99 
JapEnc         
MCV1          99 
MCV2          99  99  99  99  98  97 
PCV1         
PCV3         
Pol3          97  99  99  99  99  97 
Rota1         
RotaC         
Rubella1          99  99  99  98  98 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Czech Republic (the))
BCG
ChartChart
  98 
DTP1
ChartChart
  99  99  99  99  99 
DTP3
ChartChart
  99  99  99  99  98 
HepB3
ChartChart
  99  99  99  99 
HepB_BD
ChartChart
 
Hib3
ChartChart
  99  99  99  99 
MCV1
ChartChart
  99  99  98  98  97 
MCV2
ChartChart
  99  99  99  98  98 
PCV3
ChartChart
 
Pol3
ChartChart
  99  99  99  99  98 
RotaC
ChartChart
 

Number of districts in the country 76  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 112
From 80 to 89% 1
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 1 day to 6 weeks; Recommended for indicated groups
DTaP 5 years; Yes
DTaPHibHepIPV 9, 13, 17 weeks; 18 months; Yes
DTaPIPV 10 years; Yes
HPV 13 years; Yes
Influenza_Adult > 65 years; Yes and adults with chronic diseases, health care workers, Haj and travelers
Influenza_Pediatric Yes Children with chronic diseases
MMR 15, 21 months; Yes
Pneumo_conj Yes Recommended for indicated groups
Pneumo_ps Yes risk groups
TT 25 years; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   3 years  3 years  3 years  3years  3 years  3 years 
Nº of districts with microplans that include activities to raise immunization coverage number 86  86  86  86  86  86  86 

System performance

Total Nº districts in country number 86  86  86  86  86  86  86 
Nº districts with DTP3 coverage >=80% number 86  86  86    86  86  86 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100    100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 84  84  86    79     
% of districts with MCV1 coverage >=95% From 0 to 100% 98  98  100    92     

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No    No    No     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%     NA        100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.